^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MVA-BN-Brachyury IV vaccine

    i
    Associations
    News

    Trials

    Company:
    Bavarian Nordic
    Drug class:
    Immunostimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer (NCT04134312)
    Phase 1
    Bavarian Nordic
    Completed
    Last update posted :
    07/14/2021
    Initiation :
    01/08/2020
    Primary completion :
    01/12/2021
    Completion :
    04/06/2021
    BRAF • ER • ALK • PGR
    |
    ALK fusion • RAS mutation • ER positive + PGR positive • PGR positive
    |
    MVA-BN-Brachyury IV vaccine